Novabay Pharmaceuticals Inc P/E
Mi az Novabay Pharmaceuticals Inc P/E?
A P/E az Novabay Pharmaceuticals Inc - 0.00
Mi a P/E meghatározása?
Ár / nyereség arány a vállalat részvényárfolyamának aránya a társaság egy részvényre jutó nyereségével, amelyet tizenkét hónap alatt számítottak ki.
The price to earnings ratio is the most widely used method for determining whether shares are accurately valued in relation to one another. But the P/E ratio does not in itself indicate whether the share is a bargain. The P/E ratio depends on the market’s perception of the risk and future growth in earnings. A company with a low P/E ratio indicates that the market perceives it as a higher risk or a lower growth or both as compared to a company with a higher price to earnings ratio. The P/E ratio of a listed company’s stock is the result of the collective perception of the market as to how risky the company is and what its earnings growth prospects are in relation to that of other companies. Investors use the P/E ratio to compare their own perception of the risk and growth of a company against the market’s collective perception of the risk and growth as reflected in the current P/E ratio.
P/E a Health Care szektor a NYSEMKT-on cégekben a Novabay Pharmaceuticals Inc -hoz képest
Mit csinál Novabay Pharmaceuticals Inc?
novabay pharmaceuticals $nby is a biopharmaceutical company focusing, commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global eye care market. novabay has two distinct product categories: the neutrox™ family of products, led by avenova™ for the eye care market, neutrophase® for wound care, and cellerx™ for the dermatology market; and aganocide® compounds, led by auriclosene™. novabay is commercializing avenova, a prescription lid and lash hygiene product for the management of the chronic eye conditions of blepharitis and meibomian gland dysfunction – also known as dry eye syndrome. these difficult-to-manage conditions affect approximately 30 million americans, with an annual market potential that novabay estimates at $500 million. novabay is gaining market traction with avenova through its 35-medical direct sales representatives under veteran leadership. avenova is available for order in 90% of all pharmacies across
p/e -hoz hasonló cégek Novabay Pharmaceuticals Inc
- Richland Resources International nak P/E N/A van
- Safeplus International nak P/E N/A van
- China Yanyuan Yuhui Natl Ed Grp nak P/E N/A van
- Acusphere nak P/E N/A van
- American Oriental Bioengineering nak P/E N/A van
- Gourmet Provisions International nak P/E N/A van
- Novabay Pharmaceuticals Inc nak P/E 0.00 van
- SEL Manufacturing nak P/E 0.00 van
- China Zhong Qi Hldgs nak P/E 0.00 van
- MedSmart nak P/E 0.00 van
- Panbela Therapeutics nak P/E 0.00 van
- Epic nak P/E 0.00 van
- 2574 nak P/E 0.00 van